biotechtranslated.com
Big pharma’s “pay-to-delay” deals: Helping or hurting patients?
A few weeks ago it was announced that Jon Leibowitz has decided to leave his post at the Federal Trade Commission. Jon has been the driving force behind the FTC’s attempt to ban so called &#…